ArticleNeurogenetics2026
Significant differences in phenotype and age of onset in an SPG4 family caused by whole SPAST deletion combined with a hemizygous S44L modifier.
Article in Neurogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hereditary spastic paraplegia type 4 (SPG4) is a neurodegenerative disorder with variable age of onset and severity. We report a patient with early-onset SPG4 resulting from compound heterozygosity for a full-gene SPAST deletion and partial DPY30 loss, together with the hemizygous NM_014946.6(SPAST):c.131 C > T p.(Ser44Leu) variant. Western blot showed a similar reduction in the M87 spastin isoform in all deletion-carrying relatives, including the proband, indicating that this reduction alone does not explain the marked difference in phenotype severity: relatives had mild symptoms, whereas the proband had an early-onset, severe phenotype. This co-occurrence of a whole-SPAST deletion, partial DPY30 loss, and a hemizygous phenotype-modifier variant in one individual has, to our knowledge, not been previously reported. We hypothesise that the p.(Ser44Leu)-modified spastin may add to the effect of SPAST haploinsufficiency to produce the more severe phenotype, though the precise mechanism remains unconfirmed.
Indexed as
Identifiers
42658319What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.